Loading
companiesCompany
SOLTI Cancer Research Group
aka SOLTI
A Barcelona-based academic breast cancer group known for biomarker-driven trials that use PAM50 intrinsic subtypes to pick therapy.
Overview
Founded in 1995, SOLTI is a Spanish academic research group that designs translational breast cancer trials around molecular subtyping. PAMELA showed the HER2-enriched intrinsic subtype predicts response to dual HER2 blockade without chemotherapy, PATRICIA tested palbociclib with trastuzumab, and HARMONIA compares ribociclib with palbociclib in HER2-enriched luminal disease. SOLTI works closely with Vall d'Hebron and Hospital Clínic investigators, partners with the Breast International Group and industry, and runs window-of-opportunity and neoadjuvant designs with serial biopsies. Patient advocates sit on its scientific committee.
Headquarters
Barcelona, ES
Scorecard
All companies#50of 1243 companies, score 69
- approved products +18
- targets +4
- modalities +4
- regions +7
- 24-month regulatory events +6
- registry trials +30
3 approved, 0 in phase 3, 0 earlier, 2 targets, 1,588 registry studies. Formula on the scorecards page.
Website
Founded
1995
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to Solti, including child institutions. 48 works · 368 citations · 88% open access · 29% clinical trials · 4% reviews.
Oncology works per year
72022
122023
122024
92025
82026
Most works
- Aleix Prat25 works
- Tomás Pascual22 works
- Guillermo Villacampa18 works
- Olga Martínez‐Sáez13 works
- Eva Ciruelos13 works
- Fara Brasó‐Maristany12 works
- J.M. Ferrero-Cafiero10 works
- Blanca González‐Farré10 works
- Juan Miguel Cejalvo9 works
- Cristina Saura9 works
Most cited
Aleix Prat
Head of Medical Oncology, Hospital Clínic de Barcelona; Scientific Director, SOLTI
Breast cancer genomicsHER2-positive de-escalationPAM50 and HER2DX
Translational oncologist who built genomic tests (HER2DX) to decide which HER2-positive patients can skip chemotherapy.
Cristina Saura
Head of the Breast Cancer Unit, Vall d'Hebron University Hospital and VHIO
HER2-positive breast cancerAntibody-drug conjugatesTyrosine kinase inhibitors
Spanish breast oncologist leading DESTINY-Breast09, which moved trastuzumab deruxtecan into first-line HER2-positive disease.
Eva Ciruelos
Vice President (Vicepresidenta)
Breast cancerMedical oncologyClinical trials
Madrid breast oncologist and Vice President of the SOLTI breast cancer research group.
Mafalda Oliveira
President (Presidenta)
Breast cancerMedical oncologyEndocrine therapy
Barcelona breast oncologist who leads SOLTI, the Spanish academic breast cancer research group, and co-authors pivotal endocrine therapy trials.
Notes
top- PAM50-guided trials (PAMELA, HARMONIA)
- CDK4/6 inhibitor trials (PATRICIA)
- Window-of-opportunity and neoadjuvant designs
- BIG member group
Similar pages
not linked directly; found by shared links- CompanyAustrian Breast & Colorectal Cancer Study Group
Shares Breast International Group (BIG), Palbociclib, CDK4/6 inhibitors, HER2-positive breast cancer and the tag cooperative-group.
- CompanyBreast Cancer Trials
Shares Breast International Group (BIG), Trastuzumab, HER2-positive breast cancer, Triple-negative breast cancer (TNBC) and the tag cooperative-group.
- CompanyDanish Breast Cancer Group
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag cooperative-group.
- CompanyETOP IBCSG Partners Foundation
Shares Breast International Group (BIG), HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag cooperative-group.
- CompanyNSABP Foundation
Shares Trastuzumab, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag cooperative-group.
- CompanyNRG Oncology
Shares Breast International Group (BIG), Triple-negative breast cancer (TNBC) and the tag cooperative-group.
- CompanyOntario Clinical Oncology Group
Shares HR-positive / HER2-negative breast cancer and the tag cooperative-group.
- CompanyWest Japan Oncology Group
Shares HER2-positive breast cancer and the tag cooperative-group.
cancers
3fronts
1technologies
2drugs
3ApprovedSmall-molecule CDK4/6 inhibitor
Palbociclib · Ibrance
ApprovedSmall-molecule CDK4/6 inhibitor
Ribociclib · Kisqali
ApprovedMonoclonal antibody (anti-HER2)
Trastuzumab · Herceptin (and biosimilars, Phesgo with pertuzumab)